Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €9.84 EUR
Change Today -0.059 / -0.60%
Volume 0.0
AFF On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 7:50 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3420 Central Expressway

Santa Clara, CA 95051

United States

Phone: 408-731-5000

Fax: 408-731-5380

Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The company sells products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. Segments The company operates in two business segments, Affymetrix Core and eBioscience. Affymetrix Core segment The Affymetrix Core segment focuses on the development, manufacture, and commercialization of systems for genetic analysis in the life sciences, AgBio, and diagnostic industry. The Affymetrix Core is divided into the following business units: Expression: This business unit markets the company's GeneChip gene expression products and services; Genetic Analysis and Clinical Applications: This business unit markets the company's Axiom genotyping product line, as well as products with clinical diagnostic and research applications, including CytoScan HD, OncoScan products, and the ViewRNA in-situ hybridization platform for clinical translational research. In addition, the business unit is responsible for managing the PbA clinical partnering and licensing program which enables third-party diagnostic companies to access and develop DNA and RNA-based diagnostic tests on Affymetrix technology platforms. This business unit also markets the CytoScan Dx product, the FDA approved microarray system for post natal diagnostics of children with developmental delays and intellectual disabilities; and Life Science Reagents: This business unit sells reagents, enzymes, purification kits and biochemicals used by life science researchers and other biological and health care manufacturers, including those developing and marketing Next Generation Sequencing (NGS) products and molecular diagnostics. eBioscience segment The eBioscience segment operates with its own manufacturing, research and marketing groups. This segment specializes in the areas of flow cytometry reagents, immunoassays, microscopic imaging, other protein-based analyses, QuantiGene single and multiplex RNA solution assays, and the Procarta multiplex immunoassay product lines. During 2014, the Genetic Analysis and Clinical Applications Business Unit began marketing the ViewRNA in-situ hybridization platform for clinical translational research of RNA in tissue sections. Products The company offers a comprehensive line of products for the parallel analysis of biological systems at the gene, RNA, protein and cell level. Affymetrix Core: Through its Expression and Genetic Analysis and Clinical Applications business units, the company sells integrated systems in three principal applications: whole genome cytogenetics, genotyping and gene expression. Consumables including GeneChip arrays, molecular biology reagents and detection chemistry for these applications run on its various microarray scanner instruments. The company has three families of systems, GeneChip, GeneTitan and GeneAtlas that include instruments, consumables, and software. The company’s GeneChip instruments run arrays packaged in cartridges and its GeneTitan and GeneAtlas instruments run multiple arrays simultaneously as they are packaged in various plate or strip formats for automated high throughput processing. The QuantiGene lines of assays for the measurement of RNA, DNA or protein levels in low- to mid-plex assays are included with the Genetic Analysis and Clinical Applications business unit. The Life Science Reagents business unit offers reagents, enzymes, purification kits and biochemicals used by life science researchers. In addition, this business unit supplies other companies in its industries with products that are incorporated as part of their products. eBioscience: The eBioscience business segment offers a portfolio of antibodies and reagents for use in flow cytometry and immunoassays, as well as a range of QuantiGene (RNA and DNA assays) and Procarta Plex (protein assays) assays for low to mid-plex experiments. GeneChip The company’s GeneChip system provides an integrated solution for gene express

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFF:GR €9.84 EUR -0.059

AFF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $21.17 USD -0.70
Foundation Medicine Inc $30.02 USD -0.45
Luminex Corp $17.81 USD +0.38
Sequenom Inc $2.96 USD +0.08
Takara Bio Inc ¥1,335 JPY -10.00
View Industry Companies
 

Industry Analysis

AFF

Industry Average

Valuation AFF Industry Range
Price/Earnings 74.0x
Price/Sales 2.3x
Price/Book 2.8x
Price/Cash Flow 76.4x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit www.affymetrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.